Liraglutide

Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024

Researchers found that liraglutide, a medication commonly used for diabetes, significantly speeds up the healing of wounds in diabetic mice. The study revealed that liraglutide enhances the functions of skin cells involved in wound repair, suggesting its potential as a treatment for diabetic wounds in humans.

• Liraglutide accelerates wound closure by improving skin cell functions such as proliferation and migration.
• The healing effects of liraglutide are linked to its interaction with specific cellular proteins, Myo1c and Dock5.
• In experiments, the absence of Dock5 in skin cells prevented the healing benefits of liraglutide.

Neuropharmacology · 2024

Researchers observed that a class of diabetes drugs called GLP-1, including Exendin-4 and Liraglutide, showed promising improvements in motor function for Parkinson's disease patients in early trials. Additionally, Liraglutide demonstrated benefits for cognitive function in Alzheimer's disease patients. Ongoing studies are exploring newer versions of these drugs that may offer even better results.

• Researchers found that GLP-1 drugs improved motor activity in Parkinson's disease patients during phase II trials.
• Liraglutide showed positive effects on cognition and brain shrinkage in Alzheimer's disease patients.
• Newer GLP-1 drugs designed for better brain access are already showing improved effects in preclinical studies.

Journal of managed care & specialty pharmacy · 2024

Researchers studied the real-world use of GLP-1 medications for weight loss among obese adults without diabetes. They found that only about one-third of users continued their treatment after one year, and adherence to the medication was low, with less than a third of participants consistently taking their prescribed doses.

• Only 32.3% of participants persisted with GLP-1 therapy after one year.
• The average adherence rate was 51.0%, with only 27.2% of users taking their medication as directed.
• Semaglutide had a higher persistence rate (47.1%) compared to liraglutide (19.2%) after one year.

The American journal of emergency medicine · 2024

Researchers reviewed the use of GLP-1 agonists, medications used for diabetes and obesity, and their potential complications. They found that while these drugs can improve blood sugar control and promote weight loss, they may also cause gastrointestinal issues and other serious side effects.

• Researchers observed that common side effects of GLP-1 agonists include nausea, vomiting, and abdominal pain.
• The study noted risks of more severe complications like pancreatitis and renal issues, especially after gastrointestinal losses.
• Researchers highlighted concerns about patients seeking unregulated versions of these medications, which could lead to increased health risks.

Molecular medicine (Cambridge, Mass.) · 2023

Researchers found that liraglutide, a medication commonly used to manage blood sugar in type 2 diabetes, may also help reduce liver damage associated with non-alcoholic fatty liver disease (NAFLD). The study observed that liraglutide works by activating specific cellular pathways and inhibiting a type of cell death known as ferroptosis.

• Liraglutide improved glucose metabolism and reduced liver tissue damage in mice with type 2 diabetes and NAFLD.
• The medication activated the AMPK/ACC signaling pathway, which is important for regulating lipid metabolism.
• Inhibiting ferroptosis, a form of cell death, was crucial for restoring liver function in the diabetic mice.

American journal of physiology. Regulatory, integrative and comparative physiology · 2016

Researchers found that glucagon-like peptide-1 (GLP-1) and its long-acting versions can significantly reduce food intake and body weight. They explored the complex neural pathways in the brain that GLP-1 influences, which could lead to new obesity treatments with fewer side effects.

• GLP-1 reduces food intake primarily by acting on specific brain receptors.
• The study identified various brain regions involved in GLP-1's effects, including the hypothalamus and reward circuitry.
• Certain neural pathways activated by GLP-1 can decrease appetite without causing nausea, suggesting potential for safer obesity therapies.

JAMA · 2015

Researchers found that the weight-loss drug liraglutide was effective for adults with type 2 diabetes who are overweight or obese. Over 56 weeks, participants using liraglutide lost significantly more weight compared to those receiving a placebo. The study highlights liraglutide's potential as a weight-management option in this population.

• Participants using liraglutide (3.0 mg) lost an average of 6.0% of their body weight, compared to 2.0% with placebo.
• More than half (54.3%) of those on liraglutide (3.0 mg) lost at least 5% of their body weight, compared to only 21.4% with placebo.
• Gastrointestinal issues were more common in those taking liraglutide, but no cases of pancreatitis were reported.

The Journal of clinical investigation · 2014

Researchers observed that liraglutide, a medication used for type 2 diabetes, leads to weight loss through specific brain mechanisms. They found that liraglutide acts on certain neurons in the arcuate nucleus of the hypothalamus, which plays a key role in regulating body weight. This study highlights the importance of GLP-1 receptors in these neurons for the weight loss effects of liraglutide.

• Liraglutide does not activate GLP-1-producing neurons in the hindbrain.
• The drug binds to neurons in the arcuate nucleus and is essential for weight loss effects.
• Liraglutide stimulates specific neurons that promote weight loss while inhibiting others that encourage appetite.